Sugentech, Inc. Logo

Sugentech, Inc.

An in-vitro diagnostics company that develops and commercializes diagnostic solutions.

253840 | KO

Overview

Corporate Details

ISIN(s):
KR7253840003
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노2로 206 사무동2층 수젠텍, 대전광역시

Description

Sugentech, Inc. is an in-vitro diagnostics (IVD) company that develops and commercializes diagnostic solutions by integrating biotechnology, nanotechnology, and information technology. The company's product portfolio serves diverse healthcare settings, from large hospitals and laboratories to smaller clinics and home users. Key offerings include automated multi-immunoblot systems, point-of-care testing (POCT) platforms, and self-diagnostic kits for personal use, such as ovulation and pregnancy tests. Sugentech leverages proprietary technologies in developing high-level antibodies and advanced nanoparticles to create highly sensitive and precise immunochemical assays, underpinning its digital healthcare diagnostic platform for personalized medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
자기주식처분결과보고서
Korean 35.7 KB
2025-09-08 00:00
증권발행결과(자율공시)
Korean 6.2 KB
2025-08-29 00:00
주요사항보고서(교환사채권발행결정)
Korean 53.4 KB
2025-08-29 00:00
주요사항보고서(자기주식처분결정)
Korean 42.9 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.7 MB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-30 00:00
소속부변경
Korean 3.6 KB
2025-03-26 00:00
정기주주총회결과
Korean 30.2 KB
2025-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-18 00:00
[첨부추가]사업보고서 (2024.12)
Korean 663.6 KB
2025-03-11 00:00
감사보고서제출
Korean 25.0 KB
2025-03-10 00:00
[기재정정]의결권대리행사권유참고서류
Korean 176.4 KB
2025-03-07 00:00
주주총회소집결의
Korean 17.7 KB
2025-03-07 00:00
주주총회소집공고
Korean 167.5 KB
2025-03-07 00:00
의결권대리행사권유참고서류
Korean 170.6 KB

Automate Your Workflow. Get a real-time feed of all Sugentech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sugentech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sugentech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.